Conatus Pharmaceuticals is a biotechnology company that develops and commercializes new medicines for liver disease.
Gilde participated in the first financing round. The company has since in-licensed and successfully advanced the clinical development of its lead product Emricasan®, which treats chronic liver disease and its acute exacerbations. With 5.5 million Americans suffering from chronic liver disease or cirrhosis, liver disease is the twelfth leading cause of death in the United States.
The company was successfully listed at NASDAQ (CNAT) through an IPO in 2013.
San Diego, CA, USA